{"id":"https://openalex.org/W2032374475","doi":"https://doi.org/10.1093/eurheartj/ehq374","title":"Randomized trial of an inhibitor of secretory phospholipase A2 on atherogenic lipoprotein subclasses in statin-treated patients with coronary heart disease","display_name":"Randomized trial of an inhibitor of secretory phospholipase A2 on atherogenic lipoprotein subclasses in statin-treated patients with coronary heart disease","publication_year":2010,"publication_date":"2010-11-16","ids":{"openalex":"https://openalex.org/W2032374475","doi":"https://doi.org/10.1093/eurheartj/ehq374","mag":"2032374475","pmid":"https://pubmed.ncbi.nlm.nih.gov/21081550"},"language":"en","primary_location":{"id":"doi:10.1093/eurheartj/ehq374","doi":"https://doi.org/10.1093/eurheartj/ehq374","is_oa":false,"landing_page_url":"https://doi.org/10.1093/eurheartj/ehq374","pdf_url":null,"source":{"id":"https://openalex.org/S181568219","display_name":"European Heart Journal","issn_l":"0195-668X","issn":["0195-668X","1522-9645"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310311648","host_organization_name":"Oxford University Press","host_organization_lineage":["https://openalex.org/P4310311648","https://openalex.org/P4310311647"],"host_organization_lineage_names":["Oxford University Press","University of Oxford"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"European Heart Journal","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5060465607","display_name":"Robert S. Rosenson","orcid":"https://orcid.org/0000-0002-5599-0633","observed_orcids":["https://orcid.org/0000-0002-5599-0633"]},"institutions":[{"id":"https://openalex.org/I98704320","display_name":"Icahn School of Medicine at Mount Sinai","ror":"https://ror.org/04a9tmd77","country_code":"US","type":"education","lineage":["https://openalex.org/I1320796813","https://openalex.org/I98704320"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Robert S. Rosenson","raw_affiliation_strings":["Mount Sinai Heart\u2014Box 1030, Mount Sinai School of Medicine, One Gustave L. Levy Place, New York, NY 10029, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Mount Sinai Heart\u2014Box 1030, Mount Sinai School of Medicine, One Gustave L. Levy Place, New York, NY 10029, USA","institution_ids":["https://openalex.org/I98704320"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5020637231","display_name":"Michael D. Elliott","orcid":"https://orcid.org/0000-0002-9057-3915","observed_orcids":["https://orcid.org/0000-0002-9057-3915"]},"institutions":[{"id":"https://openalex.org/I4210152940","display_name":"Anthera Pharmaceuticals (United States)","ror":"https://ror.org/04pa38t98","country_code":"US","type":"company","lineage":["https://openalex.org/I4210152940"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michael Elliott","raw_affiliation_strings":["Anthera Pharmaceuticals, Hayward, CA 94545, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Anthera Pharmaceuticals, Hayward, CA 94545, USA","institution_ids":["https://openalex.org/I4210152940"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5056005655","display_name":"Yuri Stasiv","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210152940","display_name":"Anthera Pharmaceuticals (United States)","ror":"https://ror.org/04pa38t98","country_code":"US","type":"company","lineage":["https://openalex.org/I4210152940"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Yuri Stasiv","raw_affiliation_strings":["Anthera Pharmaceuticals, Hayward, CA 94545, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Anthera Pharmaceuticals, Hayward, CA 94545, USA","institution_ids":["https://openalex.org/I4210152940"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5006919099","display_name":"Colin Hislop","orcid":"https://orcid.org/0000-0002-1436-1988","observed_orcids":["https://orcid.org/0000-0002-1436-1988"]},"institutions":[{"id":"https://openalex.org/I4210152940","display_name":"Anthera Pharmaceuticals (United States)","ror":"https://ror.org/04pa38t98","country_code":"US","type":"company","lineage":["https://openalex.org/I4210152940"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Colin Hislop","raw_affiliation_strings":["Anthera Pharmaceuticals, Hayward, CA 94545, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Anthera Pharmaceuticals, Hayward, CA 94545, USA","institution_ids":["https://openalex.org/I4210152940"]}]},{"author_position":"middle","author":{"id":null,"display_name":"for the PLASMA II Investigators","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210152940","display_name":"Anthera Pharmaceuticals (United States)","ror":"https://ror.org/04pa38t98","country_code":"US","type":"company","lineage":["https://openalex.org/I4210152940"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"for the PLASMA II Investigators","raw_affiliation_strings":["Anthera Pharmaceuticals, Hayward, CA 94545, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Anthera Pharmaceuticals, Hayward, CA 94545, USA","institution_ids":["https://openalex.org/I4210152940"]}]},{"author_position":"middle","author":{"id":null,"display_name":"M. Imburgia","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210152940","display_name":"Anthera Pharmaceuticals (United States)","ror":"https://ror.org/04pa38t98","country_code":"US","type":"company","lineage":["https://openalex.org/I4210152940"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"M. Imburgia","raw_affiliation_strings":["Anthera Pharmaceuticals, Hayward, CA 94545, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Anthera Pharmaceuticals, Hayward, CA 94545, USA","institution_ids":["https://openalex.org/I4210152940"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113560614","display_name":"Robert Weiss","orcid":"https://orcid.org/0000-0003-4451-8373","observed_orcids":["https://orcid.org/0000-0003-4451-8373"]},"institutions":[{"id":"https://openalex.org/I4210152940","display_name":"Anthera Pharmaceuticals (United States)","ror":"https://ror.org/04pa38t98","country_code":"US","type":"company","lineage":["https://openalex.org/I4210152940"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"R. Weiss","raw_affiliation_strings":["Anthera Pharmaceuticals, Hayward, CA 94545, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Anthera Pharmaceuticals, Hayward, CA 94545, USA","institution_ids":["https://openalex.org/I4210152940"]}]},{"author_position":"middle","author":{"id":null,"display_name":"P. Underwood","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"P. Underwood","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5068737583","display_name":"David J. Ende","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210152940","display_name":"Anthera Pharmaceuticals (United States)","ror":"https://ror.org/04pa38t98","country_code":"US","type":"company","lineage":["https://openalex.org/I4210152940"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"D. Ende","raw_affiliation_strings":["Anthera Pharmaceuticals, Hayward, CA 94545, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Anthera Pharmaceuticals, Hayward, CA 94545, USA","institution_ids":["https://openalex.org/I4210152940"]}]},{"author_position":"middle","author":{"id":null,"display_name":"C. Brown","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210152940","display_name":"Anthera Pharmaceuticals (United States)","ror":"https://ror.org/04pa38t98","country_code":"US","type":"company","lineage":["https://openalex.org/I4210152940"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"C. Brown","raw_affiliation_strings":["Anthera Pharmaceuticals, Hayward, CA 94545, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Anthera Pharmaceuticals, Hayward, CA 94545, USA","institution_ids":["https://openalex.org/I4210152940"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5005603440","display_name":"Venkatesh Nadar","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210152940","display_name":"Anthera Pharmaceuticals (United States)","ror":"https://ror.org/04pa38t98","country_code":"US","type":"company","lineage":["https://openalex.org/I4210152940"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"V. Nadar","raw_affiliation_strings":["Anthera Pharmaceuticals, Hayward, CA 94545, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Anthera Pharmaceuticals, Hayward, CA 94545, USA","institution_ids":["https://openalex.org/I4210152940"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5009571253","display_name":"Russell E. Carlson","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210152940","display_name":"Anthera Pharmaceuticals (United States)","ror":"https://ror.org/04pa38t98","country_code":"US","type":"company","lineage":["https://openalex.org/I4210152940"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"R. Carlson","raw_affiliation_strings":["Anthera Pharmaceuticals, Hayward, CA 94545, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Anthera Pharmaceuticals, Hayward, CA 94545, USA","institution_ids":["https://openalex.org/I4210152940"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5059352404","display_name":"Tim Carlson","orcid":"https://orcid.org/0009-0004-0688-8028","observed_orcids":["https://orcid.org/0009-0004-0688-8028"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"T. Carlson","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5026694473","display_name":"Duane G. Wombolt","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"D. Wombolt","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5078799442","display_name":"Fadi Matar","orcid":"https://orcid.org/0000-0002-5064-0052","observed_orcids":["https://orcid.org/0000-0002-5064-0052"]},"institutions":[{"id":"https://openalex.org/I4210152940","display_name":"Anthera Pharmaceuticals (United States)","ror":"https://ror.org/04pa38t98","country_code":"US","type":"company","lineage":["https://openalex.org/I4210152940"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"F. Matar","raw_affiliation_strings":["Anthera Pharmaceuticals, Hayward, CA 94545, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Anthera Pharmaceuticals, Hayward, CA 94545, USA","institution_ids":["https://openalex.org/I4210152940"]}]},{"author_position":"middle","author":{"id":null,"display_name":"P. Rossi","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"P. Rossi","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"F. Eder","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"F. Eder","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":null,"display_name":"D. Hotchkiss","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"D. Hotchkiss","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5060465607"],"corresponding_institution_ids":["https://openalex.org/I98704320"],"apc_list":{"value":5240,"currency":"EUR","value_usd":5922},"apc_paid":null,"fwci":8.4322,"has_fulltext":false,"cited_by_count":67,"citation_normalized_percentile":{"value":0.97800294,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":89,"max":99},"biblio":{"volume":"32","issue":"8","first_page":"999","last_page":"1005"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10394","display_name":"Lipoproteins and Cardiovascular Health","score":0.9932000041007996,"subfield":{"id":"https://openalex.org/subfields/2746","display_name":"Surgery"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10394","display_name":"Lipoproteins and Cardiovascular Health","score":0.9932000041007996,"subfield":{"id":"https://openalex.org/subfields/2746","display_name":"Surgery"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11618","display_name":"Cholesterol and Lipid Metabolism","score":0.00419999985024333,"subfield":{"id":"https://openalex.org/subfields/2746","display_name":"Surgery"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12955","display_name":"Atherosclerosis and Cardiovascular Diseases","score":0.0010999999940395355,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/coronary-artery-disease","display_name":"coronary artery disease","score":0.8420000076293945},{"id":"https://openalex.org/keywords/atherogenic-lipoproteins","display_name":"atherogenic lipoproteins","score":0.9369999766349792},{"id":"https://openalex.org/keywords/ldl-cholesterol","display_name":"LDL cholesterol","score":0.8410000205039978},{"id":"https://openalex.org/keywords/non-hdl-cholesterol","display_name":"non-HDL cholesterol","score":0.8450000286102295},{"id":"https://openalex.org/keywords/vldl-particles","display_name":"VLDL particles","score":0.7760000228881836},{"id":"https://openalex.org/keywords/small-dense-ldl","display_name":"small dense LDL","score":0.9150000214576721},{"id":"https://openalex.org/keywords/statin-treated-patients","display_name":"statin-treated patients","score":0.7730000019073486},{"id":"https://openalex.org/keywords/atherosclerosis","display_name":"atherosclerosis","score":0.8379999995231628},{"id":"https://openalex.org/keywords/lipoprotein-oxidation","display_name":"lipoprotein oxidation","score":0.7210000157356262}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9591282606124878},{"id":"https://openalex.org/C2776839432","wikidata":"https://www.wikidata.org/wiki/Q954845","display_name":"Statin","level":2,"score":0.6938925981521606},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.6374593377113342},{"id":"https://openalex.org/C2777034527","wikidata":"https://www.wikidata.org/wiki/Q18032676","display_name":"Lipoprotein-associated phospholipase A2","level":4,"score":0.6350617408752441},{"id":"https://openalex.org/C3018906752","wikidata":"https://www.wikidata.org/wiki/Q844935","display_name":"Coronary heart disease","level":2,"score":0.5570870041847229},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5535500645637512},{"id":"https://openalex.org/C2909478654","wikidata":"https://www.wikidata.org/wiki/Q844935","display_name":"Atherosclerotic cardiovascular disease","level":3,"score":0.49976468086242676},{"id":"https://openalex.org/C164705383","wikidata":"https://www.wikidata.org/wiki/Q10379","display_name":"Cardiology","level":1,"score":0.47082263231277466},{"id":"https://openalex.org/C2776551241","wikidata":"https://www.wikidata.org/wiki/Q24768001","display_name":"Phospholipase A2","level":3,"score":0.46340087056159973},{"id":"https://openalex.org/C2780072125","wikidata":"https://www.wikidata.org/wiki/Q28350","display_name":"Lipoprotein","level":3,"score":0.43703776597976685},{"id":"https://openalex.org/C2778163477","wikidata":"https://www.wikidata.org/wiki/Q43656","display_name":"Cholesterol","level":2,"score":0.4239638149738312},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.41326022148132324},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.3319958448410034},{"id":"https://openalex.org/C181199279","wikidata":"https://www.wikidata.org/wiki/Q8047","display_name":"Enzyme","level":2,"score":0.10872164368629456},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0992448627948761},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.0}],"mesh":[{"descriptor_ui":"D000085","descriptor_name":"Acetates","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001055","descriptor_name":"Apolipoproteins B","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D002097","descriptor_name":"C-Reactive Protein","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D002784","descriptor_name":"Cholesterol","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D003327","descriptor_name":"Coronary Disease","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D003327","descriptor_name":"Coronary Disease","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004311","descriptor_name":"Double-Blind Method","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004334","descriptor_name":"Drug Administration Schedule","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007211","descriptor_name":"Indoles","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D007651","descriptor_name":"Keto Acids","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D014280","descriptor_name":"Triglycerides","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D019161","descriptor_name":"Hydroxymethylglutaryl-CoA Reductase Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D054497","descriptor_name":"Phospholipases A2, Secretory","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.1093/eurheartj/ehq374","doi":"https://doi.org/10.1093/eurheartj/ehq374","is_oa":false,"landing_page_url":"https://doi.org/10.1093/eurheartj/ehq374","pdf_url":null,"source":{"id":"https://openalex.org/S181568219","display_name":"European Heart Journal","issn_l":"0195-668X","issn":["0195-668X","1522-9645"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310311648","host_organization_name":"Oxford University Press","host_organization_lineage":["https://openalex.org/P4310311648","https://openalex.org/P4310311647"],"host_organization_lineage_names":["Oxford University Press","University of Oxford"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"European Heart Journal","raw_type":"journal-article"},{"id":"pmid:21081550","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/21081550","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"European heart journal","raw_type":"Clinical Trial, Phase II"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Randomized Controlled Trial","id":"https://openalex.org/study-designs/randomized-controlled-trial"},{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[],"funders":[{"id":"https://openalex.org/F4320307758","display_name":"Eli Lilly and Company","ror":"https://ror.org/01qat3289"}],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":30,"referenced_works":["https://openalex.org/W1984875752","https://openalex.org/W1990245250","https://openalex.org/W1992035893","https://openalex.org/W2006323569","https://openalex.org/W2011262952","https://openalex.org/W2012276590","https://openalex.org/W2024574408","https://openalex.org/W2029819414","https://openalex.org/W2053802334","https://openalex.org/W2059163718","https://openalex.org/W2068842527","https://openalex.org/W2073190601","https://openalex.org/W2081953245","https://openalex.org/W2084116516","https://openalex.org/W2115449326","https://openalex.org/W2116404316","https://openalex.org/W2120136430","https://openalex.org/W2120165409","https://openalex.org/W2120830651","https://openalex.org/W2120919525","https://openalex.org/W2122167768","https://openalex.org/W2128901862","https://openalex.org/W2130178468","https://openalex.org/W2132901141","https://openalex.org/W2146461935","https://openalex.org/W2147282311","https://openalex.org/W2157598033","https://openalex.org/W2170582496","https://openalex.org/W2473455258","https://openalex.org/W4250971439"],"related_works":["https://openalex.org/W2128901862","https://openalex.org/W2468896608","https://openalex.org/W2011262952","https://openalex.org/W2093395086","https://openalex.org/W1247612269","https://openalex.org/W47831966","https://openalex.org/W2132901141","https://openalex.org/W1989691811","https://openalex.org/W2398138002","https://openalex.org/W2039640108"],"abstract_inverted_index":{"AIMS:":[0],"To":[1],"investigate":[2],"the":[3,56],"effects":[4],"of":[5,37,51,55],"secretory":[6],"phospholipase":[7,15],"A2":[8,16],"(sPLA(2))":[9],"inhibition":[10],"on":[11],"plasma":[12],"lipoproteins.":[13],"Secretory":[14],"isoenzymes":[17],"promote":[18],"atherosclerosis":[19],"by":[20,138,145,156,166],"mechanisms":[21],"that":[22,108,204],"include":[23],"lipoprotein":[24,117,122],"modification,":[25],"retention,":[26],"and":[27,71,120,161,189],"oxidation.":[28],"METHODS":[29],"AND":[30],"RESULTS:":[31],"Phospholipase":[32],"Levels":[33],"And":[34],"Serological":[35],"Markers":[36],"Atherosclerosis":[38],"II":[39],"(PLASMA":[40],"II)":[41],"is":[42],"a":[43],"Phase":[44],"II,":[45],"randomized,":[46],"double-blind,":[47],"placebo-controlled":[48],"parallel-arm":[49],"study":[50],"two":[52],"once-daily":[53],"doses":[54],"novel":[57],"sPLA(2)":[58,114],"inhibitor,":[59],"1-H-indole-3-glyoxamide":[60],"or":[61,94],"varespladib":[62,82,88,129,174,205],"methyl":[63,83,89,100,130,175,206],"(Anthera":[64],"Pharmaceuticals,":[65],"Hayward,":[66],"CA,":[67],"USA).":[68],"One":[69],"hundred":[70],"thirty-five":[72],"stable":[73],"coronary":[74],"heart":[75],"disease":[76],"patients":[77],"were":[78,109],"treated":[79],"with":[80,127],"either":[81],"250":[84],"mg":[85,91,132,177,208],"once":[86,92,133,178,209],"daily,":[87,93],"500":[90,131,176,207],"placebo":[95,112],"for":[96],"8":[97],"weeks.":[98],"Varespladib":[99],"treatment":[101],"resulted":[102],"in":[103,113,200],"statistically":[104],"significant":[105],"dose-dependent":[106],"reductions":[107],"different":[110],"from":[111],"concentration,":[115],"low-density":[116],"(LDL)":[118],"cholesterol,":[119],"non-high-density":[121],"(HDL)":[123],"cholesterol.":[124],"When":[125],"compared":[126],"placebo,":[128],"daily":[134,179,210],"reduced":[135,180],"LDL":[136,152,182,191],"cholesterol":[137,144],"15%":[139,146],"(P":[140,147,158,168],"<":[141,148],"0.001),":[142,149],"non-HDL":[143],"total":[150,181],"very":[151],"(VLDL)":[153],"particle":[154,164,183,192],"concentration":[155,165,184,193],"14%":[157],"=":[159,169,187,196],"0.022),":[160],"small":[162,190],"VLDL":[163],"24%":[167],"0.030).":[170],"Relative":[171],"to":[172],"baseline,":[173],"(7%,":[185],"P":[186,195],"0.002)":[188],"(11%,":[194],"0.014).":[197],"CONCLUSION:":[198],"Reductions":[199],"atherogenic":[201],"lipoproteins":[202],"suggest":[203],"may":[211],"be":[212],"an":[213],"effective":[214],"anti-atherosclerotic":[215],"agent.":[216],"Trial":[217],"registered":[218],"at":[219],"ClinicalTrials.gov,":[220],"identifier:":[221],"NCT00525954.":[222]},"counts_by_year":[{"year":2026,"cited_by_count":3},{"year":2024,"cited_by_count":4},{"year":2023,"cited_by_count":3},{"year":2022,"cited_by_count":2},{"year":2020,"cited_by_count":4},{"year":2019,"cited_by_count":1},{"year":2018,"cited_by_count":5},{"year":2017,"cited_by_count":3},{"year":2016,"cited_by_count":5},{"year":2015,"cited_by_count":8},{"year":2014,"cited_by_count":3},{"year":2013,"cited_by_count":8},{"year":2012,"cited_by_count":10}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}